GLP-1 and SSRIs: depression, suicidal-ideation review and what the MHRA actually found

TLDR. MHRA and EMA both reviewed the 2023 to 2024 reports of suicidal ideation on GLP-1 medications. Both concluded no causal link. The reported signal appears to reflect the background rate of mental-health events in patients starting weight-loss treatment rather than a drug effect. SSRI users on GLP-1 should still be screened at baseline and monitored, but the literature does not support GLP-1 as a depression risk factor. The medication can be safely used with sertraline, escitalopram, fluoxetine, and other common SSRIs. Clinical vigilance is the right posture; reflexive avoidance is not.

In 2023, FAERS (US) and Eudravigilance (EU) databases showed an uptick in reported suicidal ideation among patients on GLP-1 medications. The MHRA (UK) launched a formal review. The EMA (Europe) ran a parallel evaluation. Both concluded in 2024 with the same finding: no causal link. Here is what the review actually examined and what patients on SSRIs should know.

The MHRA review, July 2024

The UK Medicines and Healthcare Regulatory Agency reviewed:

• Spontaneous adverse-event reports of suicidal ideation, suicide attempts and self-harm in patients on semaglutide, liraglutide and tirzepatide
• The reporting rate per 100,000 patient-years compared to background rates in obesity and diabetes populations
• Causality assessment using standard pharmacovigilance frameworks

The conclusion: "No causal association established between GLP-1 receptor agonists and suicidal ideation or self-injury."

Key points from the published assessment:

• The reporting rate was elevated above the GLP-1 medication background, but this is consistent with media-driven reporting bias rather than causal signal
• The underlying patient population (obesity and T2D) has higher baseline rates of depression and suicidality than the general population
• Temporal patterns (when symptoms appeared relative to medication initiation) did not support a pharmacological cause
• No mechanistic link between GLP-1 receptor activation and suicidality has been demonstrated

The EMA review, April 2024

The European Medicines Agency's PRAC committee reached the same conclusion: no need to update the GLP-1 product information regarding suicidality. The committee did note that "all patients should be monitored for depression and suicidal thoughts as part of standard clinical care" but explicitly stated this is general clinical practice, not GLP-1-specific.

What about FAERS in the US

The FDA's own analysis of FAERS data through 2024 was consistent with MHRA and EMA conclusions. The FDA has not updated the boxed warnings or the standard adverse-event labels for Wegovy, Zepbound or Ozempic to include suicidality.

What this means for patients on SSRIs

If you're on an SSRI (Lexapro, Zoloft, Prozac, Celexa, Paxil) for depression or anxiety and you're considering GLP-1, the regulatory consensus is:

• No causal link between GLP-1 and worsened mood
• No documented drug-drug interaction between SSRIs and GLP-1 medications
• The combination is widely prescribed without specific adverse-event signal
• Standard psychiatric care continues; monitor mood as you would on any chronic medication

What's worth doing:

1. Tell your prescribing telehealth clinician you're on an SSRI at intake. They should record it. (If they don't ask, that's a clinical-quality red flag.)
2. Tell your psychiatrist or PCP that you're starting a GLP-1. They should adjust monitoring cadence if appropriate (typically not necessary, but worth a brief check-in).
3. If your mood worsens during the first 8-12 weeks of GLP-1, attribute it appropriately. Most worsening in this window is from the GI side effects, fatigue or the calorie-restriction stress, not the GLP-1 directly. Talk to both clinicians.
4. Don't stop the SSRI when you start GLP-1. Don't change the SSRI dose. Don't add St. John's Wort or other supplements that interact with SSRIs.

What's worth flagging

The MHRA review noted that obesity itself is independently associated with elevated depression and suicidality rates. If you're starting GLP-1 with active depression, get psychiatric care first, then add the GLP-1. The medication is not a substitute for treating the underlying mood disorder.

For patients with active suicidal ideation, the standard clinical recommendation is to stabilise psychiatric care before initiating any new medication. This is true for GLP-1 as it would be for statins, blood pressure medications or any other addition to your regimen.

Programs equipped for SSRI + GLP-1 patients

Most telehealth GLP-1 programs accept patients on SSRIs without issue. The programs that handle complex psychiatric comorbidities best:

• Knownwell: full primary-care model, will coordinate with your psychiatrist
• Form Health: obesity-medicine specialists with patient-history depth
• 9amHealth: cardiometabolic focus, equipped for SSRI co-management

Cash-pay compounded programs (Mochi, Henry Meds, Medvi) will accept SSRI patients but their clinical model is transactional, not psychiatric-coordinated. Appropriate if your psychiatric care is well-managed elsewhere.

For the broader risk profile, see our honest risks article. For the BED population (which overlaps significantly with SSRI patients), see our BED article.

Frequently asked questions

Did MHRA and EMA find that GLP-1 causes depression?

No. Both agencies reviewed the 2023 to 2024 case reports of suicidal ideation and depression in GLP-1 users and concluded there was no causal link. The signal appears to reflect the background rate of mental-health events in the population starting weight-loss treatment, rather than a pharmacologic effect of the drug. Both labels were left unchanged on this concern.

Can I take GLP-1 if I am on an SSRI?

Yes, in most cases. There is no pharmacologic interaction between GLP-1 medications and common SSRIs (sertraline, escitalopram, fluoxetine, citalopram, paroxetine). Baseline mental-health screening before starting GLP-1 is reasonable, and ongoing monitoring during treatment is standard. Patients with stable depression on SSRIs typically tolerate GLP-1 without complication.

Should I tell my psychiatrist that I am starting GLP-1?

Yes. Your prescriber should know about all medications you take. The medication has no significant pharmacologic interaction with most psychiatric drugs, but psychiatrists often appreciate knowing about weight changes (which can affect dosing of weight-sensitive psychotropics like lithium) and about new GI symptoms (which can affect SSRI absorption).

What if I develop new depression symptoms after starting GLP-1?

Talk to your prescriber promptly. Most cases of mood change on GLP-1 represent either pre-existing background mental-health events, situational depression related to the weight-loss process itself (life changes, body-image shifts), or unrelated life stress. Stopping the GLP-1 to rule out a drug effect is sometimes appropriate; restarting after stabilization usually works without recurrence.

Are GLP-1 medications used to treat depression?

Not as an indication. The medication has shown weak antidepressant effects in some observational studies, likely mediated by the weight loss and metabolic improvement rather than direct mood effect. GLP-1 is not approved or recommended as a depression treatment; SSRIs, SNRIs, and other classes remain first-line for depression.